Zhejiang Shapuaisi Pharmaceutical Co vs Merck & Company: Fair Value & Quality
Both stocks run through our valuation models. Here is how Zhejiang Shapuaisi Pharmaceutical Co (603168) and Merck & Company (MRK) compare, as of Aug 25, 2026.
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Merck & Company leads: 4 to 8 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Zhejiang Shapuaisi Pharmaceutical Co
4 of 4 models see the stock below the current price.
Merck & Company
24 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Compare two other stocks
Tap a field and type again, ticker or company name.
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Zhejiang Shapuaisi Pharmaceutical Co · Health Care
Merck & Company · Health Care
Bottom line
As of Aug 25, 2026, Fair Value Calculator sees Merck & Company as the less overvalued of the two: Zhejiang Shapuaisi Pharmaceutical Co trades at ¥5.54 versus a fair value of ¥2.03 (-63%), while Merck & Company trades at $151 versus $125 (-17%).
Merck & Company has the higher quality score (70/100).
See the full analysis →More comparisons
Popular match-ups from the same sectors, all with fair value and quality score.
Related to Zhejiang Shapuaisi Pharmaceutical Co
Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupUnitedHealth Group vs Merck & CompanySee the undervalued quality stocks every month
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.